First-in-human trial launches for HER2-targeted radioligand therapy

A novel radioligand therapy targeting HER2-positive cancers has entered first-in-human trials, marking a potential new theranostic approach for patients with these malignancies.

• Design: First-in-human clinical trial (exact phase and enrollment target not reported in source).
• The therapy uses a radiolabeled ligand to target HER2, a protein overexpressed in certain breast, gastric, and other cancers.
• Limitation: As an early-phase trial announcement, no safety or efficacy data are yet available.

RadPigeon summaries are original and for information only. They are not clinical advice.